Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K38/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/185187USE OF INTERFERON FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
WO 17.09.2020
Int.Class A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
Appl.No PCT/TR2020/050211 Applicant BOGAZICI UNIVERSITESI Inventor SAHIN, Umut
The invention relates to the use of interferon, preferably interferon alpha in the treatment of amyotrophic lateral sclerosis (ALS), particularly in the treatment of ALS caused by a mutation in NEK1 gene. The invention also relates to a method of treating a patient afflicted by ALS comprising the steps of; (a) selecting a patient carrying a NEK1 variant, i.e. a mutation in NEK1, (b) administering a therapeutically effective amount of interferon, preferably interferon alpha, to the patient.
2.WO/2020/186217METHODS AND COMPOSITIONS FOR TREATMENT OF LYSOSOMAL STORAGE DISORDER
WO 17.09.2020
Int.Class A61K 35/761
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
761Adenovirus
Appl.No PCT/US2020/022761 Applicant CHILDREN'S HOSPITAL MEDICAL CENTER Inventor PAN, Dao
Methods for improving at least one neurological function in a subject that has or is suspected of having a neurologic lysosomal storage disorder using a rapamy cin compound. Also provided herein are treatment of such a neurologic lysosomal storage disorder with the rapamy cin compound.
3.WO/2020/186247COMPOSITIONS AND METHODS FOR PROMOTING ISLET VIABILITY AND ENHANCING INSULIN SECRETION
WO 17.09.2020
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2020/022822 Applicant UNIVERSITY OF VIRGINIA PATENT FOUNDATION Inventor LAURIE, Gordon, W.
Compositions and methods for regenerating pancreatic islet viability and/or cell proliferation in vitro, ex vivo, and/or in vivo; and/or for regenerating glucose-stimulated insulin secretion; and/or for regenerating viability and/or cell proliferation of a transplanted pancreatic islets; and/or for preventing and/or inhibiting rejection of a transplanted islets; and/or for pancreatic islet transplantation; and/or for treating a symptom of a condition, disorder, or disease associated with abnormal insulin responsiveness to glucose are provided. In some embodiments, the compositions include a peptide and/or a pharmaceutically acceptable salt thereof, and/or a biologically active fragment, analog, or derivative thereof, wherein the peptide, the pharmaceutically acceptable salt thereof, and/or the biologically active fragment, analog, or derivative thereof has an amino acid sequence of any of SEQ ID NOs: 1-60, or any combination thereof.
4.WO/2020/182596DOSAGE FORM COMPRISING A POLYMERIC MATRIX
WO 17.09.2020
Int.Class A61K 9/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
Appl.No PCT/EP2020/055810 Applicant EVONIK OPERATIONS GMBH Inventor MOERS, Christian
The invention is concerned with a dosage form, comprising a polymeric matrix, comprising one or more polymer(s) and a biologically active ingredient, wherein the polymeric matrix comprises 10 % by weight or more of the one or more polymer(s) and wherein the one or more polymer(s) are polymerized from a monomer mixture comprising the monomers (a) 70 to 95 % by weight of 2-ethylhexyl methacrylate (EHMA) and ethyl methacrylate (EMA) or 2-ethylhexyl methacrylate (EHMA) and methyl methacrylate (MMA), (b) 0 to 25 % by weight of a C2 to C6 hydroxy-alkylester of acrylic acid or methacrylic acid, (c) 2.5 to 20 % by weight of a C2 to C8 alkyl ester of acrylic acid or of methacrylic acid with a quaternary cationic group in the alkyl group.
5.WO/2020/185826COMPOSITIONS AND METHODS FOR PROTECTING TYPE 2 ALVEOLAR EPITHELIAL CELLS (AEC2)
WO 17.09.2020
Int.Class A61K 38/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
08Peptides having 5 to 11 amino acids
Appl.No PCT/US2020/021980 Applicant LUNG THERAPEUTICS, INC. Inventor WASNICK, Roxana
Provided herein are compositions comprising caveolin-l (Cav-l) peptides and methods of using said compositions to protect type 2 alveolar epithelial cells from injury- or disease-induced apoptosis as well as increase the expression of the ABCA3 and SpC proteins.
6.WO/2020/185996METHODS OF TREATING ACUTE CORONARY SYNDROMES
WO 17.09.2020
Int.Class A61K 31/7004
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7004Monosaccharides having only carbon, hydrogen and oxygen atoms
Appl.No PCT/US2020/022250 Applicant TUFTS MEDICAL CENTER, INC. Inventor SELKER, Harry
The invention provides methods for treating and preventing acute coronary syndromes (ACS). The methods involve initiation of the administration of glucose-insulin-potassium (GIK) soon (e.g., within 3 hours) after the onset of ACS symptoms.
7.WO/2020/186256METHODS OF TREATING IMMUNOGLOBULIN A NEPHROPATHY (IGAN) USING AXL DECOY RECEPTORS
WO 17.09.2020
Int.Class C12N 9/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
10Transferases (2.)
12transferring phosphorus containing groups, e.g. kinases (2.7)
Appl.No PCT/US2020/022860 Applicant ARAVIVE INC Inventor MCINTYRE, Gail
Compositions and methods are provided for treating immunoglobulin A nephropathy (IgAN) in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL protein activity, for example by inhibition of the binding interaction between AXL and its ligand GAS6.
8.WO/2020/183465COMPOSITIONS COMPRISING DRAGLINE SPIDER SILK
WO 17.09.2020
Int.Class D01F 8/02
DTEXTILES; PAPER
01NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
FCHEMICAL FEATURES IN THE MANUFACTURE OF MAN-MADE FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
8Conjugated, i.e. bi- or multicomponent, man-made filaments or the like; Manufacture thereof
02from cellulose, cellulose derivatives, or proteins
Appl.No PCT/IL2020/050286 Applicant SEEVIX MATERIAL SCIENCES LTD. Inventor ITTAH, Shmuel
Compositions comprising at least one major ampullate spidroin protein (MaSp)-based fiber, a polymer bound to the MaSp-based fiber, and optionally a further polymer having a molecular weight in the range of 1000 Da to 1000 kDa, are provided. Further, methods for preparation of same are provided.
9.WO/2020/186155SYNTHETIC NEUROMODULATORY PEPTIDES
WO 17.09.2020
Int.Class A61K 38/07
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
07Tetrapeptides
Appl.No PCT/US2020/022623 Applicant LACTOCORE, INC. Inventor MALYSHEV, Anton
A pharmaceutical composition comprising a synthetic neuromodulatory peptide is described. The invention discloses neuromodulatory peptides as defined in the claims and methods of using such molecules for therapeutic application. The neuromodulatory peptides included in the composition have been found to be effective in treatment of depression and other mood disorders, including anxiety.
10.WO/2020/186235COMPOSITIONS AND METHODS FOR MODULATING CGRP SIGNALING TO REGULATE INTESTINAL INNATE LYMPHOID CELLS
WO 17.09.2020
Int.Class A61K 38/23
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
23Calcitonins
Appl.No PCT/US2020/022803 Applicant THE BROAD INSTITUTE, INC. Inventor XAVIER, Ramnik
The present invention provides novel compositions and methods based on the discovery of the mechanisms and gene expression programs associated with homeostatic ILC2s and proinflammatory ILC2s that drive tissue inflammation. Immune signaling abnormalities in the small intestine can trigger chronic type 2 inflammation. Applicants analyzed 58,067 immune cells from the mouse small intestine by single-cell RNA-seq at steady state and after induction of a type 2 inflammatory reaction to ovalbumin. Cell type composition and cell programs shifted in response to inflammation, especially in ILC2s. A key transcript in the inflammation-induced program in intestinal KLRG1+ ILC2s was exon 5 of Calca, encoding the alpha-calcitonin gene-related peptide (a-CGRP). a-CGRP antagonized IL-25 -induced activation of intestinal ILC2s and reduced their frequency in an ovalbumin reaction model. α-CGRP activated a cAMP response, which suppressed ILC2 proliferation. In homeostasis, α-CGRP was expressed by two subsets of ChAT+ enteric neurons, and genetic perturbation of α-CGRP increased the proportion of intestinal ILC2s and of Tuft cells. The results demonstrate that a-CGRP-mediated neuronal signaling suppresses ILC2 expansion and maintains type 2 immunity homeostasis.